Trial Profile

Effect of Sarilumab on Patient-reported Outcomes in Patients With Moderately to Severely Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sarilumab (Primary) ; Azathioprine; Chloroquine; Hydroxychloroquine; Leflunomide; Methotrexate; Methotrexate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms SariPRO
Sponsors Sanofi

06 Jun 2020 Results assessing cognitive impairment presented at the 21st Annual Congress of the European League Against Rheumatism.
06 Jun 2020 Results assessing effectiveness of sarilumab on several PROs using the RAID (Rheumatoid Arthritis Impact of Disease) score presented at the 21st Annual Congress of the European League Against Rheumatism
26 Aug 2019 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com